The present study was undertaken to determine the target engagement of a novel, highly specific anti‐MMP9 antibody within the PDAC tumour microenvironment, and to define its therapeutic efficacy in combination with nab‐paclitaxel‐based cytotoxic chemotherapy in pre‐clinical PDAC models. Here, MMP9 is linked to neoplasm.